Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Nektar Therapeutic Systems (NKTR) Com Stk Nil Par Value (CDI)

Sell:$17.88 Buy:$17.89 Change: $0.23 (1.27%)
NASDAQ:1.35%
Market closed |  Prices as at close on 19 August 2019 | Switch to live prices |
Sell:$17.88
Buy:$17.89
Change: $0.23 (1.27%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 19 August 2019 | Switch to live prices |
Sell:$17.88
Buy:$17.89
Change: $0.23 (1.27%)
Market closed |  Prices as at close on 19 August 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

Contact details

Address:
455 Mission Bay Blvd S
SAN FRANCISCO
94158-2158
United States
Telephone:
+1 (415) 4825300
Website:
www.nektar.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NKTR
ISIN:
US6402681083
Market cap:
$3.15 billion
Shares in issue:
175.27 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Robert Chess
    Independent Chairman of the Board
  • Howard Robin
    President, Chief Executive Officer, Director
  • Gilbert Labrucherie
    Chief Financial Officer, Senior Vice President
  • John Nicholson
    Chief Operating Officer, Senior Vice President
  • Jillian Thomsen
    Senior Vice President - Finance, Chief Accounting Officer
  • Stephen Doberstein
    Senior Vice President, Research & Development and Chief Research & Development Officer
  • Wei Lin
    Senior Vice President - Clinical Development and Head of Nektar's Oncology Programs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.